Barclays raised the firm’s price target on Abbott (ABT) to $162 from $159 and keeps an Overweight rating on the shares. The firm recommends using the pullback following the in-line Q3 report as a buying opportunity. The shares were discounting a slightly stronger beat for Q3, the analyst tells investors in a research note. Barclays views the business weakness as temporary, and expects Abbott’s portfolio to return to growth toward the high end of its historical ranges in 2026 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $142 from $144 at Evercore ISI
- Abbott price target raised to $146 from $141 at Raymond James
- Abbott price target raised to $146 from $142 at Wells Fargo
- Abbott Laboratories: Strong Growth Prospects and Stable Financial Health Drive Buy Rating
- Abbott Laboratories Reports Strong Q3 2025 Earnings